PDCD1 and hepatocellular carcinoma: In the last decade, studies have shown that different molecular typing influences the response to treatment and prognosis of HCC, such as the expression status of programmed cell death protein 1 (PD-1), suggesting different sensitivity to immunotherapy (Scheiner et al., 2019; Feng et al., 2020a).